Mechanisms of Loss of Response to Adalimumab in Crohn's Disease

被引：0
|
作者：
Wolf, Douglas C.
Hauenstein, Scott
Lockton, Steven
Singh, Sharat
机构：
来源：
GASTROENTEROLOGY | 2013年 / 144卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S775 / S775
页数：1
相关论文
共 50 条
  • [21] Adalimumab for the treatment of Crohn's disease
    Devlin, Shane M.
    Panaccione, Remo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (07) : 1011 - 1019
  • [22] Pharmacokinetics of adalimumab in Crohn’s disease
    David Ternant
    Konstantinos Karmiris
    Severine Vermeire
    Céline Desvignes
    Nicolas Azzopardi
    Theodora Bejan-Angoulvant
    Gert van Assche
    Gilles Paintaud
    European Journal of Clinical Pharmacology, 2015, 71 : 1155 - 1157
  • [23] Adalimumab induction for Crohn's disease
    Cottone, M
    Mocciaro, F
    Scimeca, D
    GASTROENTEROLOGY, 2006, 130 (06) : 1929 - 1929
  • [24] Adalimumab in pediatric Crohn's disease
    Patel, Ashish S.
    Suarez, Lisbet D.
    Rosh, Joel R.
    IMMUNOTHERAPY, 2016, 8 (02) : 127 - 133
  • [25] Long-term durability of response to adalimumab in Crohn's disease
    Chaparro, M.
    Panes, J.
    Garcia, V.
    Merino, O.
    Nos, P.
    Domenech, E.
    Penalva, M.
    Garcia-Planella, E.
    Esteve, M.
    Hinojosa, J.
    Andreu, M.
    Munoz, F.
    Gutierrez, A.
    Mendoza, J. L.
    Barrio, J.
    Barreiro-de Acosta, M.
    Vera, I.
    Vilar, P.
    Cabriada, J. L.
    Montoro, M. A.
    Aldeguer, X.
    Saro, C.
    Gisbert, J. P.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (04) : 685 - 690
  • [26] Pharmacokinetics of adalimumab in Crohn's disease
    Ternant, David
    Karmiris, Konstantinos
    Vermeire, Severine
    Desvignes, Celine
    Azzopardi, Nicolas
    Bejan-Angoulvant, Theodora
    van Assche, Gert
    Paintaud, Gilles
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (09) : 1155 - 1157
  • [27] Metastatic Crohn's disease. Response to adalimumab dose intensification
    Lazaro Saez, Marta
    Hernandez Martinez, Alvaro
    Bendezu Garcia, Roger Alvaro
    Rodriguez Manrique, Marco Antonio
    Simon Lopez, Francisca
    Medina Estevez, Emilia
    Vega Saenz, Jose Luis
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2012, 35 (05): : 321 - 325
  • [28] Genetic of vitamin D as predictor of response to adalimumab in Crohn's Disease
    Cusato, J.
    Ribaldone, D. G.
    Bertani, L.
    Antonucci, M.
    Tomasello, C.
    Caviglia, G. P.
    Dibetto, S.
    Mangia, M.
    Astegiano, M.
    D'Avolio, A.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S058 - S061
  • [29] EVALUATION OF PREDICTORS OF DURABLE CLINICAL RESPONSE TO INFLIXIMAB AFTER SECONDARY LOSS OF RESPONSE TO ADALIMUMAB AMONG PATIENTS WITH CROHN'S DISEASE
    Younis, Adam
    Barnes, Edward L.
    Herfarth, Hans H.
    GASTROENTEROLOGY, 2019, 156 (06) : S1139 - S1140
  • [30] Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab
    Ma, Christopher
    Huang, Vivian
    Fedorak, Darryl K.
    Kroeker, Karen I.
    Dieleman, Levinus A.
    Fedorak, Richard N.
    GASTROENTEROLOGY, 2014, 146 (05) : S457 - S458
12345